RTC
SMMT icon

Riverview Trust Company’s Summit Therapeutics SMMT Stock Holding History

Riverview Trust Company’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-1,000
Closed -$7K – 240
2021
Q2 		$7K Buy
+1,000
New +$6.56K 0.01% 218

Other funds holding SMMT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Riverview Trust Company's SMMT Position: Q3 2021 in Review

Riverview Trust Company sold out of Summit Therapeutics (SMMT) in Q3 2021, closing a stake of 1,000 shares — an estimated $7K sold.

Riverview Trust Company first reported a position in SMMT in Q2 2021 and held it in 1 quarter. The position peaked at $7K in Q2 2021. 54 funds tracked by Wall St. Rank hold SMMT as of Q3 2021.

  • Riverview Trust Company reported no remaining Summit Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Riverview Trust Company sold 1,000 Summit Therapeutics shares in Q3 2021, an estimated $7K.
  • Riverview Trust Company first reported a position in Summit Therapeutics in Q2 2021 and held it in 1 quarter.
  • Riverview Trust Company's Summit Therapeutics position peaked at $7K in Q2 2021.
  • 54 funds tracked by Wall St. Rank held Summit Therapeutics as of Q3 2021.

Based on Riverview Trust Company's 13F filing for Q3 2021, filed 14 Oct 2021.